TrialHeadache2018

100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.

Noah Rosen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.